Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intra-ovarian PRP in Low Ovarian Reserve
NCT05279560Active, not recruiting
- Sponsor
- University of Lübeck
- Start
- Mar 2022
- Primary completion
- Apr 2025
- Modality
- Adoptive Cell Transfer
- Countries
- 1
01
Overview
Randomised, single-blind trial of autologous platelet-rich plasma in Diminished Ovarian Reserve (DOR) and premature ovarian insufficiency (POI) (2 arms), sponsored by University of Lübeck. Primary endpoint: Ovarian response. Started Mar 2022; status: active, not recruiting.
02
Drugs
autologous platelet-rich plasma
03
Conditions
Diminished Ovarian Reserve (DOR)premature ovarian insufficiency (POI)
Beyond the preview
Go deeper on NCT05279560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05279560.